Hematological and extrahematological toxicity of high-dose (hd) mitoxantrone (MITO) and melphalan (L-PAM) as conditioning regimen prior to peripheral blood progenitor cell (PBPC) autograft was evaluated in 113 lymphoma patients (87 at disease onset). Autograft was the final part of a hd-sequential (HDS) chemotherapy program, including a debulkying phase (1-2 APO ± 2 DHAP courses) and then sequential administration of hd-cyclophosphamide, methotrexate (or Ara-C) and etoposide, at 10 to 30 day intervals. Autograft phase included: (1) hd-MITO, given at 60 mg/m 2 on day −5; (2) hd-L-PAM, given at 180 mg/m 2 on day −2; (3) PBPC autograft, with a median of 11 × 10 6 CD34 ؉ /kg, or 70 × 10 4 CFU-GM/kg, on day 0. A rapid hematological recovery was observed in most patients, with ANC Ͼ500/L and Plt Ͼ20 000/l values reached at a median of 11 and 10 days since autograft, respectively. The good hemopoietic reconstitution allowed the delivery of consolidation radiotherapy (RT) to bulky sites in 53 out of 57 candidate patients, within 1 to 3 months following autograft; five of these patients required back-up PBPC re-infusion due to severe post-RT pancytopenia. Few severe infectious complications were recorded. There was one single fatal event due to severe pancytopenia following whole abdomen RT. Cardiac toxicity was evaluated as left ventricular ejection fraction (LVEF), monitored by cardiac radionuclide scan. LVEF prior to and after autograft was significantly reduced (median values: 55% vs 46%) in 58 evaluated patients; however, a significant increase to a median value of 50% was observed in 45 patients evaluated at 1 to 3 years since autograft. At a median follow-up of 3.6 years, 92 patients are alive, with a 7-year overall survival projection and 6.7-year failure-free survival projection of 77% and 69%, respectively. We conclude that a conditioning regimen with hd-MITO/L-PAM fits well within the HDS program. It implies good tolerability and reversible cardiotoxicity and it may have contributed to the good long-term outcome observed in this series of patients. Leukemia (2001) 15, 256-263. 
Introduction
In the last decade high-dose chemotherapy and autograft have significantly improved the outcome of lymphoma patients. This approach is presently the first choice for relapsed high grade non-Hodgkin's and Hodgkin's lymphoma. [1] [2] [3] [4] Moreover, in the last few years evidence has been produced pointing towards a role for autograft as first-line treatment for both low and high grade poor prognosis non-Hodgkin's lymphoma. [5] [6] [7] [8] [9] [10] [11] [12] The wide applicability of this procedure has been possible due to the advantages offered by peripheral blood progenitor cells (PBPC) in reducing hematological toxicity. [13] [14] [15] [16] Correspondence: C Tarella, Cattedra di Ematologia, Via Genova 3, 10126 Torino, Italy; Fax: 0039-011-696.3737 2 The ease deriving from the excellent tolerability of PBPC procedures probably slowed down the efforts aimed to look for innovative and possibly more effective conditioning regimens. In fact, most autograft programs employed nowadays are based on conditioning regimens designed several years ago, such as TBI + cyclophosphamide (CY), or regimens containing nitrosurea or melphalan (L-PAM), such as BEAM, CBV or BEAC. [17] [18] [19] [20] [21] Looking for a better conditioning regimen, one should not only consider the antitumor activity of a given drug combination, but should be concerned with its toxicity as well. Today, hematological toxicity is not as severe as it used to be, due to the availability of mobilized PBPC. Thus, efforts should rather be addressed to reduce extra-hematological toxicity of intensive programs.
Lymphoma patients seem to benefit from anthracyclinecontaining conditioning regimens. Unfortunately, their use at high dosage has been hampered by the risk of cardiac toxicity. [22] [23] [24] Mitoxantrone (MITO), a molecule derived from anthracenedione, has been proposed as an alternative. Several studies have shown that this drug can be safely used alone or in combination, at doses significantly higher than those commonly employed in conventional protocols. [25] [26] [27] [28] [29] [30] In spite of consistently reported good tolerability, there is presently a lack of studies conducted on wide and homogeneous groups of patients and with an appropriately long follow-up. Moreover, few studies have been specifically addressed to analyze cardiac function prior and following high-dose MITO.
In this study we investigated the tolerability of a combination of high-dose MITO and L-PAM in 113 lymphoma patients. Autograft was the final part of a high-dose (hd) sequential chemotherapy program. 9, 10, 15 The study was aimed to evaluate at short, medium and long term: (1) hematological toxicity; (2) extra-hematological toxicity and in particular cardiac function evolution; (3) life expectancy, of patients completing the whole program including autograft. The results indicate that MITO can be safely employed in conditioning regimens before PBPC autograft, with an acceptable hematological and extra-hematological toxicity; there was a certain cardiac toxicity but this was unexpectedly reversible, at least in part. Finally, the prolonged long-term survival indicates that the combination MITO/L-PAM may contribute to the effectiveness of hd-sequential chemotherapy programs.
Patients and methods

Patients
A retrospective analysis on overall tolerability and cardiac toxicity of the combination of hd-MITO + L-PAM was carried out by collecting data from 113 lymphoma patients treated at the University Division of Hematology of Turin, Italy between 1991 and 1998. All patients were part of study protocols based on the use of the original or modified high-dose sequential (HDS) chemotherapy regimens. They received hd-MITO/L-PAM followed by PBPC autograft as the conclusive phase of the program. The protocols, including the final PBPC autograft, were approved by the local Ethical Committee and all patients gave written informed consent to both chemotherapy program and autograft. All enrolled patients had a biopsyproven diagnosis of lymphoma. They received the HDS program either at disease onset, if they presented with advancedstage and poor prognostic features, or at disease relapse. Eligibility criteria included normal heart, renal and liver functions as well as negative tests for HIV, HBsAg and HCV. All patients underwent routine staging procedure before starting the chemotherapy program; their main clinical features are shown in Table 1 .
HDS treatment schedules
All patients received either the original (64 patients) HDS chemotherapy regimen or one of the two 'second-generation' schedules, named i-HDS and C-HDS. 9, 10, 15 The original HDS regimen included the sequential administration of: (1) Leukemia ing prior to the hd-phase with four APO + two DHAP (dexametasone/hd-Ara-C/cisplatin) courses. In the subsequent hd-phase, the CY/VP16 sequence was inverted, in order to schedule PBPC harvest at the end of the hd-scheme. In addition, a chemotherapy-free interval of 30 days was included prior to hd-CY in order to allow adequate marrow repopulation and optimal progenitor cell mobilization. 31 In the chemotherapy-free interval, a total of three hd-dexamethasone courses (dexamethasone at 40 mg/day for 4 consecutive days) were administered every 10 days. G-CSF (Filgrastim) was given at 5 g/kg/ day following CY, VP16, Ara-C and autograft, until myelopoietic recovery or completion of harvesting procedures. The HDS chemotherapy schedules, ie original HDS, i-HDS and C-HDS, are detailed in Figure 1 . All patients presenting with bulky disease received additional radiotherapy (RT) to bulky sites 1 to 2 months after autograft. Twenty-six patients received the HDS program as salvage after disease recurrence. Their previous treatments consisted of MACOP-B (four patients), CHOP (seven patients), MINE (one patient), chlorambucil (two patients) and ABVD or MAMA hybrid schemes (12 patients). Only six patients had also received involved field radiotherapy.
Collection and evaluation of hemopoietic progenitors
PBPC were mobilized and collected following hd-CY or, in a few patients, following hd-Ara-C or hd-VP16. A BM harvest
Figure 1
Scheme of the original and modified HDS regimens. i-HDS, intensified HDS; C-HDS, hd-Ara-C-HDS; CY, cyclophosphamide; MTX, methotrexate; VP16, etoposide; MITO, mitoxantrone; L-PAM, melphalan; APO, adriamycin-prednisone-vincristine; DHAP, dexamethasone-hd-Ara-C-cisplatin; CDDP, cisplatin; PBPC, peripheral blood progenitor cells.
was performed at the end of the hd-phase in those patients with low amounts of harvested PBPC (see below). To predict number and timing of leukaphereses, circulating CD34
+ cells along with cell blood counts were evaluated daily starting from day +9 following chemotherapy administration to harvesting procedure completion. CD34
+ cell evaluation was carried out according to published procedures. 31 Peripheral blood buffy-coat cells were collected when the WBC count was at least 1000/l and PB CD34
+ cells Ͼ10/l. Leukaphereses were performed using continuous-flow blood cell separators (Cobe-Spectra, Lakewood, CO, USA or Fresenius, Schweinfurt, Germany) and 7-13 blood liters (median 8.9 l) were processed for each procedure.
Progenitor estimation in leukapheresis products was carried out by evaluating both CD34
+ cells and CFU-GM. The in vitro colony-forming assay was performed as previously described. 31 Values of 30 × 10 4 CFU-GM/kg and 5 × 10 6 CD34 + cells/kg were taken as the minimal required dose of harvested progenitors for patients to be enrolled in the autografting program with PBPC only. In 12 patients where lower amounts of progenitors were harvested, additional BM harvest was combined with leukapheresis collection.
MITO/L-PAM administration and post-autograft supportive care
The combined administration of hd-MITO and hd-L-PAM was used as conditioning regimen in all patients. 25 MITO was given i.v. at 60 mg/m 2 in three divided doses of 1 h each every 2 h on day −5: this schedule allowed an adequate interval for mitoxantrone clearance from plasma prior to PBPC reinfusion, in accordance with reported pharmacokinetic data. 25 ,27,28 L-PAM was given i.v. at 180 mg/m 2 in three divided doses of 30 min each every 2 h on day −2; PBPC were reinfused 2 days later. Since 1996, G-CSF was added following autograft in order to accelerate hemopoietic recovery.
32 G-CSF was given i.v. over 1 h at 5 g/kg/day starting on day +1 until neutrophil count reached 500/l on 2 consecutive days. The entire pretransplant program was carried out in ordinary, non-protected rooms, whereas for the autograft phase patients were generally admitted to a dedicated inpatient bone marrow transplant unit. During the recovery phase following autograft patients were managed with a common protocol for prophylaxis and therapy of pancytopenia-related complications. Briefly, antibiotic prophylaxis included oral ciprofloxacin (500 mg twice a day) + fluconazole (150 mg) + i.v. acyclovir (250 mg three times a day); in the case of fever Ͼ38°C, blood culture and chest X-ray were performed, then patients were empirically treated with i.v. mezlocillin + amikacin + vancomycin; this latter is now added only in the case of positive surveillance culture for gram+ cocci; if the fever was of undetermined origin and persisted after 36-48 h, mezlocillin was replaced by imipenem; i.v. amphotericin was added in a few cases with fever persisting for 36-48 more hours. Antibiotics were continued until the temperature reverted to normal values for at least 2 consecutive days along with the return of the ANC to Ͼ500/l. Parenteral antibiotics were also started in the absence of fever whenever patients were unable to continue oral prophylactic antibiotics, due to mucositis. Irradiated, leukocyte-filtered, single-donor platelet concentrates or, less frequently, multiple-donor irradiated platelet concentrates were given when platelet count was less than 20 000/l; irradiated, leukocyte-filtered packed RBCs were given if hemoglobin was less than 8.0 g/dl.
Outcome parameters
Physical examination + cell blood count (CBC) and common biochemical blood tests were performed daily during recovery following autograft. Thereafter, all patients had a complete restaging assessment every 3 months during the first year, and every 6 months afterwards. A thorough reassessment of renal, hepatic and cardiac functions were scheduled prior to autograft and at given intervals thereafter. In particular, cardiac function was monitored by careful clinical examination, EKG and chest X-ray. No patients had to be excluded from autograft due to cardiac dysfunction. A cardiac radionuclide scan was performed at the start of treatment and prior to autograft in all patients; in addition, 58 patients had their cardiac function evaluated prior to autograft and within 6 months after autograft; 45 of these 58 patients were subsequently studied at 1 to 3 years since autograft. Their clinical characteristics did not differ from those of the other patients. Thus, this group was highly representative of the whole series of 113 patients.
Long-term outcome of patients completing the whole program was evaluated as overall survival and failure-free survival. Survival duration was measured from treatment start to the day of death or last follow-up evaluation. Failure-free survival duration was calculated from autograft up to the first adverse event, ie failure to reach complete remission (CR), relapse, treatment-related or disease-related deaths or the date the patient was last known to be in remission. The actuarial duration of overall survival (OS) and failure-free survival (FFS) were plotted as curves according to Kaplan and Meier product-limit method. 33 The closing date for analysis was 30 June 1999.
Results
Haematological toxicity
Median number of grafted progenitors and time to post-graft hemopoietic recovery are reported in Table 2 . There were six patients with delayed recovery; three of them had prolonged requirement of transfusion support; a rapid hematological recovery was the rule in all remaining patients and values of ANC Ͼ500/L and Plts Ͼ20 000/l were reached at a median of 11 (range 8-31) and 10 (range 7-60) days since autograft, respectively. No statistically significant differences were observed in short-term hemopoietic recovery between original and modified HDS regimens. Indeed, platelet and RBC trans- fusion requirement was similar for the three regimens employed.
Hemopoietic reconstitution was stable in most patients. This is shown by median CBCs recorded at 1, 3 and 6 months after autograft (see Table 3 ). The stable hemopoietic reconstitution is further proved by RT feasibility at 1 to 3 months following autograft. In fact, RT could be delivered to bulky sites in 53 out of 57 candidate patients. Five more patients required reinfusion of back-up PBPC due to severe pancytopenia following RT. These patients had been transplanted with a number of progenitor cells that was not out of the range of the whole patient population. Unfortunately, there was a toxic death in a patient with persistent, severe pancytopenia following whole abdomen RT. The pancytopenia persisted after reinfusion of back-up PBPC. This was the single toxic event occurring in this series of patients. Long-term engraftment was durable in all evaluable patients, as shown by CBCs recorded at 1, 3 and 6 years after autograft (Table 4) . Plts Ͻ20 000/l in one patient with secondary myelodysplasia, and in one with bone marrow relapse of NHL.
Leukemia
Extrahematological toxicity and cardiac function evaluation
Autograft was relatively well tolerated, with few severe infectious complications, as shown in Table 5 . Mucositis of grades III-IV was the most frequent complication, occurring in 35 patients. Fever was also quite common, occurring in the majority of patients. Mild and reversible elevation of liver enzymes was observed in 10 patients, and bilirubin elevation up to five-fold normal value occurred in 36 patients. However, no long-term irreversible liver damage ever occurred. No evidence of hepatic venous occlusive disease was ever observed nor severe toxicities of the kidney and the urinary tract. There were no severe acute cardiac toxicities during early recovery following autograft, with the exception of a transient recurrence of atrial fibrillation. During the first 100 days postautograft, four patients complained of palpitation, associated with sinus tachycardia, requiring medical therapy in three of them (propanolol in two, digoxin in one). Two of these patients had disease recurrence and required further chemotherapy; the other two patients are long-term, disease-free survivors and are no longer symptomatic. One more patient had an overt heart failure occurring immediately after mediastinal RT delivered at 2 months post-autograft. She was an obese patient who had an early disease recurrence, with a rapid and fatal progression.
In the long term, two patients developed symptomatic heart failure: one is a 55-year-old man treated with HDS for disease recurrence after CHOP-based first-line therapy; the other is a 32-year-old obese subject who is now in continuous remission of high-grade lymphoma 5 years after HDS + mediastinal RT. In both patients, symptoms subsided after medical therapy. These two patients had a marked left ventricular ejection fraction (LVEF) reduction, as detected by radionuclide cardiac-scan after autograft. However, both patients improved their LVEF a few months later, similarly to that observed in the whole patient population (see below). One more patient had a transient atrial fibrillation occurring at 4 years after autograft + mediastinal RT which spontaneously subsided. No other symptomatic cardiac disfunctions have been recorded among 92 survivors. Thirteen patients had to be rescued due to disease recurrence following HDS. Salvage therapy consisted of hd-chemotherapy and a second autograft in five patients and allogeneic transplant in four patients. All were able to receive retreatment without major cardiac dysfunctions.
Cardiac function was investigated by radionuclide cardiac- scan. Virtually all patients were evaluated at the start of treatment and before autograft. LVEF value decreased following the hd-phase, although the difference was not statistically significant (data not shown). Three patients underwent autograft with LVEF values slightly below 40%. LVEF values prior to autograft and within 6 months after autograft could be compared in 58 patients. Ten of them received mediastinal RT after autograft. A LVEF decrease was recorded in 51 patients and median values recorded prior to and after autograft were significantly different, as shown in Figure 2 . A marked reduction of LVEF was seen in four out of the 10 evaluable patients who received mediastinal RT. Finally, 45 out of 58 patients could be subsequently assessed at 1 to 3 years thereafter. Thirty-four patients displayed a spontaneous improvement of their LVEF and median LVEF value recorded at longterm was significantly higher compared to the post-graft evaluation ( Figure 3) . LVEF improvement was not confined to patients with mild or moderate cardiac function impairment; in fact, patients with post-graft LVEF lower than 50% also dis- played a significant improvement at Ͼ1 year following autograft ( Figure 4) .
As shown in Table 6 , the rate of post-graft LVEF reduction was similar between patients receiving the original or the modified HDS schemes as well as between patients receiving a total anthracyclin dose lower or higher than 200 mg/m 2 . A significant LVEF improvement was recorded in all these subgroups at Ͼ1 year following autograft. In addition, other parameters, including sex, age (less or more than 45 years old), mediastinal RT, previous treatments, did not significantly influence post-graft LVEF reduction and its subsequent improvement.
Overall outcome
To date, 92 patients are alive at 1 to 7 years since disease onset. At a median follow-up of 3.8 years, the 7-year OS curve Table 6 Changes of LVEF at 3-6 months and at Ͼ1 year after autograft according to treatment schedule and previous anthracyclin dose is projected to 77%. Eighty-two patients are surviving in continuous complete remission, at 0.5 up to 6.7 years after autograft. At a median follow-up of 3 years, the 6.5-year FFS curve is projected to 69%. Besides the single toxic death, 17 patients had a short-lasting PR or disease progression following HDS; 13 more patients reached CR and subsequently relapsed. All these latter patients were able to receive salvage therapy, consisting of conventional therapy (one patient), RT (three patients), second high-dose chemoradiotherapy with PBPC or BM autograft (five patients) or allogeneic transplantation (four patients). Salvage therapy was safely delivered without any fatal toxicity and 11 out of 13 patients were able to reach a prolonged second remission.
Discussion
The association MITO/L-PAM was first described in 1989. 25 Several aspects make this drug combination particularly suitable for lymphoma patients: it includes a high-dose anthracenedione derivative, closely related to the anthracycline family, a keystone in the treatment of lymphoma; L-PAM is an alkylating-agent particularly effective in lymphoid malignancies as well; finally, the absence of TBI makes the scheme very practical and easy to use. In spite of these considerations, MITO/L-PAM has not been paid particular attention to date and, following the original observation, only one other study has evaluated the toxicity and efficacy of this regimen, on a relatively small series of patients, mostly affected by solid tumor. 30 The present study was addressed to evaluate shortand long-term outcome in a large series of 113 lymphoma patients receiving hd-MITO/L-PAM followed by PBPC autograft. All patients have been followed for a minimum of 1 year and up to 7 years.
Post-transplant engraftment was fast, as usually observed in autograft with PBPC. The use of G-CSF following PBPC infusion may have contributed to the rapid ANC recovery as already reported by others and our group. 32, 34, 35 Blood counts were satisfying in the weeks immediately following short-term engraftment. This is a crucial issue, since it implies the possibility of delivering full-dose consolidation radiotherapy in most patients requiring it. RT on bulky sites is a very effective additional measure in chemotherapy-treated high grade lymphoma patients. 36 RT constitutes an integral part of our HDS programs, and has presumably contributed to the very good results reported in poor-risk lymphoma patients. 10, 37 Hence, maintainance of good blood counts in the first months following autograft is of definite importance in every program including RT following hd-chemotherapy.
Unfortunately, one patient had a prolonged pancytopenia following abdominal RT and subsequently died of infection. This is the only toxic death observed in this series of patients. It is possible that whole abdomen RT following HDS is poorly tolerated; for this reason we no longer use this approach, and rather, we prefer limited field RT in the case of abdominal bulky masses. Four patients could not undergo RT due to low CBC and five more patients experienced severe pancytopenia following consolidation RT. In these patients a further backup PBPC re-infusion was necessary. Thus, following MITO/L-PAM, hematological reconstitution is usually good, apart from a few exceptions raising a certain problem in delivering eventual consolidation RT in a small though not negligible fraction of patients. This issue should not be disregarded and we suggest collecting as many PBPC as possible in order to have extra PBPC if needed.
Leukemia
The prolonged follow-up enabled us to monitor the longterm CBC pattern. This analysis was obviously carried out only in disease-free patients, thus in the absence of any further cytotoxic treatment. There was no graft failure ever, and CBC values were constantly good; even those few patients with values lower than normal in the first months following transplant showed a progressive improvement of their CBCs. The long-term pattern of CBC is consistent with our previous observations on PBPC stable and durable engraftment, confirming those data on a wider number of cases and with a definitely longer follow-up. 38 It has always been our policy to use large numbers of PBPC for autograft. Also in this study most patients received Ͼ5 × 10 6 CD34 + /kg or Ͼ30 × 10 4 CFU-GM/kg. These values are in line with those previously reported in a study conducted on a large number of patients transplanted with PBPC. 39 Thus, graft failure is quite unlikely if such PBPC numbers are employed. On the other hand, the long-term CBC outcome in subjects receiving fewer PBPC remains unpredictable.
There were no severe extra-hematological complications. Advanced-grade oro-pharyngeal mucositis was very common. This complication was probably more pronounced with MITO/L-PAM compared to other schemes. Moreover, lowgrade liver toxicity was also commonly observed in about 30% of cases, with liver function tests going back to normal values within a few days. A severe toxic left over was never observed and MITO/L-PAM seems globally to share an overimposable toxicity pattern with other conditioning schemes commonly employed in patients with lymphoma.
Due to the high MITO dose employed, the potential cardiac toxicity was carefully evaluated. From a clinical point of view there was no particular adverse event with the exception of one case of atrial fibrillation and two episodes of heart failure, in any case promptly resolved following medical treatment. Heart function was evaluated by cardiac radionuclide scan, commonly accepted as the most reliable test to assess druginduced cardiac toxicity. 40, 41 In the present study, LVEF was systematically evaluated before and after transplant in as many as 58 patients. This function assessment was significantly reduced from 55% to 46% median values. Such a reduction is in line with the one mentioned in a previous study on hd-MITO. 28 Only very few patients showed post-graft LVEF values below 40%. Moreover, we should not forget that in the present study the MITO/L-PAM conditioning was preceded by several other cytotoxic treatments, including a preliminar debulkying with doxorubicin, and a sequence of hd drugs such as CY and, in most patients, followed by RT, often delivered to the thoracic region. Thus, in spite of other potentially cardiotoxic treatments, LVEF reduction following hd-MITO was globally acceptable and not higher than the one observed with other commonly employed regimens such as CY/TBI. 42 Post-graft LVEF reduction had little clinical impact. There were only two cases of limited-grade heart failure. In fact, cardiac function was shown to improve with the passage of time. LVEF was better in most cases 2-3 years after transplant, as assessed by cardiac radionuclide scan. Heart failure has been reported as a possible late complication in approximately 14% of long-term surviving lymphoma patients treated with conventional-dose anthracycline-containing regimens. 43 Anthracycline-linked heart damage dramatically increases with cumulative doses over 550 mg/m 2 and there is little evidence of its reversibility. [22] [23] [24] [43] [44] [45] [46] [47] From this viewpoint our data may be of interest. We are well aware that hd-MITO implies a certain cardiac toxicity, however, this toxicity has little clinical impact. In addition, the use of a conditioning regimen such as MITO/L-PAM following an intensive highdose sequential schedule does not preclude at least a partial recovery of cardiac function. A more prolonged follow-up is required to assess if LVEF recovery can be complete with time. Additional studies might verify whether reversibility selectively applies to MITO-induced cardiotoxicity or whether it also concerns the damage linked to the other potentially cardiotoxic drugs included in the programs.
Besides tolerability, any conditioning regimen needs careful evaluation of efficacy as well. Unfortunately, this aspect could not be adequately assessed in this study. Autograft was the final part of a very intensive hd-program and it is very difficult to distinguish between MITO/L-PAM activity and the activity of the hd-phase itself. Moreover, most patients undergoing autograft were already in clinical remission. Long-term outcome of grafted patients was very good anyway, in terms of both overall and failure-free survival. Thus we can at least conclude that advanced-stage lymphoma patients completing the whole hd-program including autograft have a high chance of prolonged disease-free survival. The final autograft phase seems to fit well into the hd-sequential program and probably contributes in a non-measurable way to the good clinical outcome observed in these patients. In addition, due to its good tolerability, autograft did not eventually prevent the administration of rescue treatments in those patients who subsequently relapsed. Most of these patients were able to undergo a second-line high-dose regimen with autograft or allogeneic transplantation, often with achievement of a second remission. Thus, feasibility of effective salvage therapies may have further improved the overall life expectancy of this series of patients.
Dose size is of critical importance in the autograft setting, since the whole antitumor effect relies on the drugs delivered. Thus, efforts have been directed in the last years to developing new conditioning regimens including both good tolerability and drug dose intensification. [48] [49] [50] We think the association of hd-MITO + L-PAM fits well in this new line of conditioning regimens and seems promising for patients with lymphoma.
